Background: Skin lesional from Atopic Dermatitis (AD) patients characterized by. elevated expression of the T2 cytokine axis takes place in ad, in which interleukin (IL)-4 and IL-13 play a major role. Aim: This work aims to determine the efficacy of immunomodulatory biologic treatments in atopic dermatitis patients. Materials and Methods: A systematic search was performed over different medical databases to identify Dermatology studies, which studied the outcome of the Biologic group versus the Placebo group of atopic dermatitis patients. Using the meta-analysis process, either with fixed or random-effects models, we conducted a meta-analysis on one of the following scores: eczema area and severity index (EASI), dermatology life quality index (DLQI) score and patient-oriented eczema measure (POEM) score as the main study outcomes. Results: Five studies were identified involving 1298 patients, with 834 patients in the Biologic group, and 464 patients in the placebo group. The meta-analysis process revealed that using the random-effects model, the meta-analysis process revealed a highly significant increase in mean EASI score in the Biologic group (p = 0.003). Using the random-effects model, the meta-analysis process revealed a non-significant difference in mean DLQI and POEM scores in the Biologic group (p < 0.05). Conclusion: To conclude, inflammatory disease, characterized by intense itching and eczema. Patients may need immunobiological therapies to achieve proper disease control.
Select your language of interest to view the total content in your interested language
Annals of Medical and Health Sciences Research received 15898 citations as per google scholar report